Market revenue in 2024 | USD 937.0 million |
Market revenue in 2030 | USD 1,006.6 million |
Growth rate | 1.2% (CAGR from 2025 to 2030) |
Largest segment | Conventional |
Fastest growing segment | Molecular |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Molecular, Conventional |
Key market players worldwide | BioMerieux SA, Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG ADR, Becton Dickinson & Co, Qiagen NV, Thermo Fisher Scientific Inc, Meridian Bioscience, Hologic, Inc. |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hospital acquired infections diagnostics market will help companies and investors design strategic landscapes.
Conventional was the largest segment with a revenue share of 53.5% in 2024. Horizon Databook has segmented the U.S. hospital acquired infections diagnostics market based on molecular, conventional covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. is witnessing a significant rise in the number of HAI cases. According to the Centers for Disease Control and Prevention (CDC), HAIs affect approximately 1 in 25 hospital patients in the U.S. each year.
Common types of HAIs include surgical site infections, central line-associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia. In July 2024, a study by the National Institutes of Health revealed an increase in both hospital-acquired infections and antibiotic resistance.
The findings are based on data collected from 120 U.S. hospitals over a five-year period, spanning January 2018 to December 2022, which included the COVID-19 pandemic. The increasing prevalence of HAIs leads to longer hospital stays, higher healthcare costs, and greater patient morbidity and mortality, necessitating effective prevention and control measures.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. hospital acquired infections diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. hospital acquired infections diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account